Mesenchymal stem cells and cardiac repair: principles and practice.

Jozef Bartunek, Atta Behfar, Marc Vanderheyden, William Wijns, Andre Terzic

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) are cluster of differentiation 34 (CD34)-CD45-negative nonhematopoietic progenitors derived typically from the stromal fraction of the bone marrow. These stem cells display multipotent properties with a demonstrable differentiation capacity along multiple mesodermal lineages. In the setting of myocardial injury, preclinical studies indicate benefit of both autologous and allogeneic transplantation in line with a recognized immunotolerant profile. Initial clinical experience supports the value of mesenchymal stem-cell-based therapy in ischemic cardiomyopathy. Experience is however limited to naïve mesenchymal stem cells, with efforts underway to identify optimal means of enhancing the cardiogenic potential of transplanted cells through guided cardiopoiesis with the ultimate aim of achieving standardized therapy of the ischemic myocardium.

Original languageEnglish (US)
Pages (from-to)115-119
Number of pages5
JournalJournal of Cardiovascular Translational Research
Volume1
Issue number2
DOIs
StatePublished - Jun 2008

Fingerprint

Mesenchymal Stromal Cells
Multipotent Stem Cells
Autologous Transplantation
Homologous Transplantation
Cell- and Tissue-Based Therapy
Cardiomyopathies
Cell Differentiation
Myocardium
Bone Marrow
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Genetics
  • Genetics(clinical)
  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Mesenchymal stem cells and cardiac repair : principles and practice. / Bartunek, Jozef; Behfar, Atta; Vanderheyden, Marc; Wijns, William; Terzic, Andre.

In: Journal of Cardiovascular Translational Research, Vol. 1, No. 2, 06.2008, p. 115-119.

Research output: Contribution to journalArticle

Bartunek, Jozef ; Behfar, Atta ; Vanderheyden, Marc ; Wijns, William ; Terzic, Andre. / Mesenchymal stem cells and cardiac repair : principles and practice. In: Journal of Cardiovascular Translational Research. 2008 ; Vol. 1, No. 2. pp. 115-119.
@article{5eee59057beb4058a12152741ab17995,
title = "Mesenchymal stem cells and cardiac repair: principles and practice.",
abstract = "Mesenchymal stem cells (MSCs) are cluster of differentiation 34 (CD34)-CD45-negative nonhematopoietic progenitors derived typically from the stromal fraction of the bone marrow. These stem cells display multipotent properties with a demonstrable differentiation capacity along multiple mesodermal lineages. In the setting of myocardial injury, preclinical studies indicate benefit of both autologous and allogeneic transplantation in line with a recognized immunotolerant profile. Initial clinical experience supports the value of mesenchymal stem-cell-based therapy in ischemic cardiomyopathy. Experience is however limited to na{\"i}ve mesenchymal stem cells, with efforts underway to identify optimal means of enhancing the cardiogenic potential of transplanted cells through guided cardiopoiesis with the ultimate aim of achieving standardized therapy of the ischemic myocardium.",
author = "Jozef Bartunek and Atta Behfar and Marc Vanderheyden and William Wijns and Andre Terzic",
year = "2008",
month = "6",
doi = "10.1007/s12265-008-9021-5",
language = "English (US)",
volume = "1",
pages = "115--119",
journal = "Journal of Cardiovascular Translational Research",
issn = "1937-5387",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Mesenchymal stem cells and cardiac repair

T2 - principles and practice.

AU - Bartunek, Jozef

AU - Behfar, Atta

AU - Vanderheyden, Marc

AU - Wijns, William

AU - Terzic, Andre

PY - 2008/6

Y1 - 2008/6

N2 - Mesenchymal stem cells (MSCs) are cluster of differentiation 34 (CD34)-CD45-negative nonhematopoietic progenitors derived typically from the stromal fraction of the bone marrow. These stem cells display multipotent properties with a demonstrable differentiation capacity along multiple mesodermal lineages. In the setting of myocardial injury, preclinical studies indicate benefit of both autologous and allogeneic transplantation in line with a recognized immunotolerant profile. Initial clinical experience supports the value of mesenchymal stem-cell-based therapy in ischemic cardiomyopathy. Experience is however limited to naïve mesenchymal stem cells, with efforts underway to identify optimal means of enhancing the cardiogenic potential of transplanted cells through guided cardiopoiesis with the ultimate aim of achieving standardized therapy of the ischemic myocardium.

AB - Mesenchymal stem cells (MSCs) are cluster of differentiation 34 (CD34)-CD45-negative nonhematopoietic progenitors derived typically from the stromal fraction of the bone marrow. These stem cells display multipotent properties with a demonstrable differentiation capacity along multiple mesodermal lineages. In the setting of myocardial injury, preclinical studies indicate benefit of both autologous and allogeneic transplantation in line with a recognized immunotolerant profile. Initial clinical experience supports the value of mesenchymal stem-cell-based therapy in ischemic cardiomyopathy. Experience is however limited to naïve mesenchymal stem cells, with efforts underway to identify optimal means of enhancing the cardiogenic potential of transplanted cells through guided cardiopoiesis with the ultimate aim of achieving standardized therapy of the ischemic myocardium.

UR - http://www.scopus.com/inward/record.url?scp=54349083877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54349083877&partnerID=8YFLogxK

U2 - 10.1007/s12265-008-9021-5

DO - 10.1007/s12265-008-9021-5

M3 - Article

C2 - 20559905

AN - SCOPUS:54349083877

VL - 1

SP - 115

EP - 119

JO - Journal of Cardiovascular Translational Research

JF - Journal of Cardiovascular Translational Research

SN - 1937-5387

IS - 2

ER -